Horizon Scanning

It is a challenge for health plans and clinicians to know what emerging technologies are in the preapproval phase and what their clinical, financial, and risk impacts might be. This is where we come in.

The Hayes Horizon Scanning Solution identifies innovative and potentially disruptive health technologies that are in various stages of the regulatory approval process. Our Research Analysts continually investigate new technologies that are on the horizon or in the early stages of clinical investigation, as well as the testing of existing technologies that may be seeking approval for new clinical applications. Hayes Horizon Scanning helps you track emerging technologies before you need to make decisions. Accessed through the Hayes Knowledge Center, Hayes Horizon Scanning addresses the following fundamental questions to help our clients forecast emerging technologies:

  • Is this emerging technology new or replacing an existing technology?
  • Where is this technology in the FDA regulatory process?
  • When will this technology be commercially available in the market?
  • What is the projected use, cost, and financial impact of this technology?

Coapsys® Mitral Annuloplasty Device

A left ventricular remodeling device for the treatment of functional mitral regurgitation consisting of anterior and posterior epicardial pads connected by a transventricle tension chord that are surgically implanted on a closed, beating heart.

SEQureDx™ Trisomy 21 Test

A molecular genetic test for noninvasive detection of Down syndrome from fetal nucleic acids found in maternal plasma or serum in the first or second trimester of pregnancy. 

Prostate Cancer Antigen 3 (PCA3) Genetic Assay

A genetic assay that quantifies expression of the PCA3 gene in urine; intended to supplement current screening methods to help decide if a biopsy is required in men suspected of having prostate cancer.

Cimzia® (Certolizumab Pegol)

An injectable biologic agent for management of moderate to severe Crohn’s disease refractory to current care therapies.

SEPET™ Selective Plasma Filtration Therapy

An extracorporeal liver assist device consisting of single-use plasma filtration cartridges designed to be placed on a standard kidney dialysis system; proposed as adjuvant treatment for patients with chronic liver failure experiencing an acute episode and hospitalized for hepatic encephalopathy.